Trial Profile
A phase I trial to evaluate safety and efficacy of BRS 001 (StemVacs ) in patients with cancer .
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jul 2020
Price :
$35
*
At a glance
- Drugs BRS 001 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 22 Jun 2020 According to the Therapeutic Solutions International media release, he Company has filed data from the trial with the FDA, as part of IND 17448.
- 25 Jul 2018 New trial record
- 31 May 2018 Results published in the Therapeutic Solutions International Media Release